Where does Expression Pathology, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Expression Pathology, Inc. ranks #7,693 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Expression Pathology, Inc. hold?

Expression Pathology, Inc. holds 42 US utility patents granted between 2015 and 2020, spanning 8 technology areas.

What is Expression Pathology, Inc.'s Innovation Score?

Expression Pathology, Inc. has an Innovation Score of 30.8 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Expression Pathology, Inc. focus on?

Expression Pathology, Inc.'s top technology area is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties) with 42 patents, ranking #360 of 7,863 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Expression Pathology, Inc.'s patent grant rate increasing or decreasing?

Expression Pathology, Inc.'s recent grant velocity is -80% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Expression Pathology, Inc.'s patents?

Expression Pathology, Inc.'s patents average 13.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Expression Pathology, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Expression Pathology, Inc.

USPTO PatentsView assignee record - 42 granted patents across 8 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Expression ranks #7,693 of 49,997 tracked US assignees by granted-patent volume, with 42 patents across 8 technology areas.

#7,693
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (30.8/100): 13.0
avg claims per patent: -80%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7693 · US Corporation #7,693 · 42 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 42 grants
UPPER-Q #7,693/49,997
PHOTO-FINISH Durect
CPC-NARROW G01N · 8 areas
INNOV-THIN 30.8/100
CLAIMS-RICH 13.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -80% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Durect Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Expression’s 30.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.0 pts (42%) Velocity 0.0 pts (0%) Breadth 10.0 pts (32%) Claim depth 7.8 pts (25%)

Qualcomm Incorporated · highest

85
Allen-vanguard · near

31
Expression Pathology · this assignee

31
Petram · near

31
Savage Arms · near

31
Vanderbilt Chemicals · near

31
3D Lighting… · lowest

7

What this shows Expression's Innovation Score is 30.8/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Expression?

Each dot is one of Expression’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Expression’s own 13.0 claims/patent is at or below the 16.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Expression vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Expression's grants concentrate

Expression Pathology, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2016 (9 grants) versus a trough of 3 in 2015. By volume, Expression sits between Durect Corporation and Fisher & Company, Incorporated.

Durect

42
Easton Diamond Sp…

42
Energy and Enviro…

42
Ethernovia

42
Fiserv

42
Fpinnovations

42
Fuji Shoji

42
Fisher & Incorpor…

42
Expression Pathol… ◀

42

What this shows Expression holds 42 patents at rank #7,693, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Expression

By rank, the assignees closest to #7,693 in granted patent volume.

Leaders in G01N (Investigating OR Analysing Materials BY Determining Their…)

Other assignees with the most granted patents in Expression's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Expression, neither rank-band nor same-CPC leaders (those blocks stay above). In G01N (Investigating OR Analysing Materials BY Determining Their…), Expression ranks #360 of 7,863 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (31 here).

Savage Arms, Inc. 31 Petram Technologies, Inc. 31 Allen-vanguard Corporation 31 Vanderbilt Chemicals, LLC 31

Expression's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Expression Pathology, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	7.1%
2016	9	21.4%
2017	8	19.0%
2018	8	19.0%
2019	7	16.7%
2020	7	16.7%

Which technologies does Expression Pathology, Inc. patent most?

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 42

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 15

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07K - Peptides 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

H01J - Electric Discharge Tubes OR Discharge Lamps 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C12Y - Enzymes 2

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Expression Pathology, Inc.'s patent record in context - here's where to go next.

Expression Pathology, Inc.'s lead technology class is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties), 100% of its portfolio - see every assignee active in that class. Explore G01N
Ranked #7,693 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Expression Pathology, Inc. against Durect Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.